Published in Cancer Cell on November 01, 2007
Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol (2010) 7.75
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
In-depth characterization of the microRNA transcriptome in a leukemia progression model. Genome Res (2008) 3.55
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med (2008) 2.49
The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood (2010) 2.33
Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood (2009) 2.26
Leukaemogenesis: more than mutant genes. Nat Rev Cancer (2010) 2.16
Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics (2012) 1.61
Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA (2009) 1.48
The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Br J Cancer (2010) 1.47
MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly (2009) 1.43
MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. J Hematol Oncol (2012) 1.42
n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis (2009) 1.41
MiR-223 suppresses cell proliferation by targeting IGF-1R. PLoS One (2011) 1.41
RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci (Landmark Ed) (2012) 1.37
Functional integration of microRNAs into oncogenic and tumor suppressor pathways. Cell Cycle (2008) 1.33
Expression and function of micro-RNAs in immune cells during normal or disease state. Int J Med Sci (2008) 1.30
MicroRNA function in myeloid biology. Blood (2011) 1.30
MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis (2010) 1.24
Selective upregulation of microRNA expression in peripheral blood leukocytes in IL-10-/- mice precedes expression in the colon. J Immunol (2011) 1.23
MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol (2013) 1.22
MicroRNA-223 is neuroprotective by targeting glutamate receptors. Proc Natl Acad Sci U S A (2012) 1.21
MicroRNA programs in normal and aberrant stem and progenitor cells. Genome Res (2011) 1.17
Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood (2010) 1.16
miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma. J Invest Dermatol (2013) 1.15
Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663. J Hematol Oncol (2011) 1.14
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol (2008) 1.14
MicroRNA 203 Modulates Glioma Cell Migration via Robo1/ERK/MMP-9 Signaling. Genes Cancer (2013) 1.12
MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct (2011) 1.10
MicroRNAs in mutagenesis, genomic instability, and DNA repair. Semin Oncol (2011) 1.09
Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer (2011) 1.08
Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. J Biomed Biotechnol (2011) 1.05
Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome (2009) 1.05
MicroRNAs as Haematopoiesis Regulators. Adv Hematol (2013) 1.03
A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS One (2013) 1.02
miRNAs in human cancer. Methods Mol Biol (2012) 1.01
TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood (2010) 1.01
MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia (2012) 0.96
MiRNAs, epigenetics, and cancer. Mamm Genome (2008) 0.96
Progress and challenge of microRNA research in immunity. Front Genet (2014) 0.93
Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits. Neoplasia (2010) 0.93
MicroRNAs: new players in acute myeloid leukaemia. Br J Cancer (2009) 0.93
A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle (2014) 0.92
The miR-223/nuclear factor I-A axis regulates glial precursor proliferation and tumorigenesis in the CNS. J Neurosci (2013) 0.91
RUNX1: A microRNA hub in normal and malignant hematopoiesis. Int J Mol Sci (2013) 0.91
HTLV-1 Tax mediated downregulation of miRNAs associated with chromatin remodeling factors in T cells with stably integrated viral promoter. PLoS One (2012) 0.91
MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today (2012) 0.90
MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways. PLoS One (2013) 0.90
Post-translational modifications of Runx1 regulate its activity in the cell. Blood Cells Mol Dis (2009) 0.90
AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation. Leukemia (2015) 0.89
The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma. Arch Biochem Biophys (2014) 0.89
CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis. Adv Hematol (2009) 0.88
MicroRNA profiling in human neutrophils during bone marrow granulopoiesis and in vivo exudation. PLoS One (2013) 0.88
Genome-wide methylated CpG island profiles of melanoma cells reveal a melanoma coregulation network. Sci Rep (2013) 0.87
MicroRNA control of myelopoiesis and the differentiation block in acute myeloid leukaemia. J Cell Mol Med (2012) 0.86
Transcriptional fine-tuning of microRNA-223 levels directs lineage choice of human hematopoietic progenitors. Cell Death Differ (2013) 0.85
Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr Med Chem (2008) 0.85
The microRNAs involved in human myeloid differentiation and myelogenous/myeloblastic leukemia. J Cell Mol Med (2008) 0.85
DNA methylation and microRNAs in cancer. World J Gastroenterol (2012) 0.85
PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex. Cell Rep (2013) 0.85
MiR-223 suppresses endometrial carcinoma cells proliferation by targeting IGF-1R. Am J Transl Res (2014) 0.85
MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer. Sci Rep (2014) 0.84
MicroRNA involvement in immune activation during heart failure. Cardiovasc Drugs Ther (2011) 0.84
Acquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon. Blood (2013) 0.84
Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes. Epigenetics (2013) 0.84
MicroRNAs and their applications in kidney diseases. Pediatr Nephrol (2014) 0.84
Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator. Cancer Immunol Immunother (2015) 0.83
Smoking and microRNA dysregulation: a cancerous combination. Trends Mol Med (2013) 0.83
Long and short non-coding RNAs as regulators of hematopoietic differentiation. Int J Mol Sci (2013) 0.83
Differential microRNA expression following infection with a mouse-adapted, highly virulent avian H5N2 virus. BMC Microbiol (2014) 0.82
microRNA Regulation and Its Consequences in Cancer. Curr Pathobiol Rep (2012) 0.82
MicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tune. Int J Mol Sci (2013) 0.82
Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy. Hum Gene Ther Methods (2013) 0.82
Clinical significance of long noncoding RNA SPRY4-IT1 in melanoma patients. FEBS Open Bio (2016) 0.81
Novel RNA-binding properties of the MTG chromatin regulatory proteins. BMC Mol Biol (2008) 0.81
Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells. BMC Genomics (2015) 0.80
RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1). J Cell Biochem (2010) 0.80
MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol (2013) 0.80
Noncoding RNAs in Acute Myeloid Leukemia: From Key Regulators to Clinical Players. Scientifica (Cairo) (2012) 0.80
Emerging Roles for MicroRNAs in Perioperative Medicine. Anesthesiology (2016) 0.79
miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia. Mol Cancer (2015) 0.79
MicroRNAs in Control of Stem Cells in Normal and Malignant Hematopoiesis. Curr Stem Cell Rep (2016) 0.79
Evaluation of microRNA expression in patient bone marrow aspirate slides. PLoS One (2012) 0.78
RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1. Oncogenesis (2015) 0.78
MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia. Blood Cancer J (2016) 0.78
MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol (2015) 0.77
The Role of MicroRNAs in Hematopoietic Stem Cell and Leukemic Stem Cell Function. Ther Adv Hematol (2011) 0.77
Reprogramming immune responses via microRNA modulation. Microrna Diagn Ther (2013) 0.77
MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1. PLoS One (2012) 0.77
Peripheral blood methylation profiling of female Crohn's disease patients. Clin Epigenetics (2016) 0.77
Intrinsic Toxicity of Unchecked Heterochromatin Spread Is Suppressed by Redundant Chromatin Boundary Functions in Schizosacchromyces pombe. G3 (Bethesda) (2015) 0.76
MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia. Leuk Lymphoma (2014) 0.76
miRNA and TMPRSS2-ERG do not mind their own business in prostate cancer cells. Immunogenetics (2013) 0.76
A Double Negative Loop Comprising ETV6/RUNX1 and MIR181A1 Contributes to Differentiation Block in t(12;21)-Positive Acute Lymphoblastic Leukemia. PLoS One (2015) 0.76
MicroRNAs in Myeloid Hematological Malignancies. Curr Genomics (2015) 0.76
MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO. PLoS Genet (2016) 0.75
MicroRNA-223 regulates granulopoiesis but is not required for HSC maintenance in mice. PLoS One (2015) 0.75
Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia. Chin Med J (Engl) (2016) 0.75
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med (2005) 12.18
A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell (2005) 9.22
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science (2002) 6.05
Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol (2006) 4.71
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A (2008) 4.26
MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol (2007) 4.02
Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes. Nat Genet (2010) 3.66
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature (2008) 3.53
Human chromosome 7: DNA sequence and biology. Science (2003) 3.02
Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood (2002) 2.77
Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. Nat Genet (2009) 2.72
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med (2004) 2.71
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr (2010) 2.64
Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet (2005) 2.51
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood (2009) 2.41
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol (2009) 2.26
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood (2011) 2.13
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood (2008) 2.09
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood (2006) 2.06
Aspergillus galactomannan enzyme-linked immunosorbent assay cross-reactivity caused by invasive Geotrichum capitatum. J Clin Microbiol (2006) 2.05
53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions. Cell (2013) 2.05
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2011) 2.02
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol (2009) 2.00
A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol (2008) 1.97
Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem (2006) 1.93
MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovasc Res (2008) 1.87
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PLoS One (2010) 1.83
CEP290 mutations are frequently identified in the oculo-renal form of Joubert syndrome-related disorders. Am J Hum Genet (2007) 1.82
Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood (2012) 1.78
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood (2009) 1.78
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood (2013) 1.74
Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol (2011) 1.73
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood (2011) 1.59
PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood (2002) 1.59
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol (2008) 1.58
Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol (2012) 1.57
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response. Leuk Lymphoma (2012) 1.56
Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood (2007) 1.48
Myelodysplastic syndromes in patients under 50 years old: a single institution experience. Leuk Res (2005) 1.43
MKS3/TMEM67 mutations are a major cause of COACH Syndrome, a Joubert Syndrome related disorder with liver involvement. Hum Mutat (2009) 1.43
MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. J Hematol Oncol (2012) 1.42
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood (2006) 1.41
Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. Leuk Lymphoma (2010) 1.40
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood (2005) 1.39
Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease. Leuk Res (2008) 1.39
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene (2005) 1.36
MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks. Mol Cell Biol (2008) 1.36
Stage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases. Proc Natl Acad Sci U S A (2002) 1.36
Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res (2005) 1.35
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood (2004) 1.33
Novel TMEM67 mutations and genotype-phenotype correlates in meckelin-related ciliopathies. Hum Mutat (2010) 1.32
Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood (2012) 1.31
Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood (2002) 1.30
Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. J Clin Invest (2007) 1.30
Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol (2008) 1.28
Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol (2011) 1.27
Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res (2010) 1.21
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica (2005) 1.19
Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res (2006) 1.18
8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chromosomes Cancer (2005) 1.17
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica (2008) 1.14